TFS Capital’s CytomX Therapeutics CTMX Stock Holding History

TFS Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-61,010	Closed	-$946K	–	85
2017 Q2	$946K	Buy	61,010 +46,703	+326%	+$704K	0.37%	50
2017 Q1	$247K	Buy	+14,307	New	+$188K	0.08%	419

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TFS Capital's CTMX Position: Q3 2017 in Review

TFS Capital sold out of CytomX Therapeutics (CTMX) in Q3 2017, closing a stake of 61,010 shares — an estimated $946K sold.

TFS Capital first reported a position in CTMX in Q1 2017 and held it in 2 quarters. The position peaked at $946K in Q2 2017. 97 funds tracked by Wall St. Rank hold CTMX as of Q3 2017.

TFS Capital reported no remaining CytomX Therapeutics position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 61,010 CytomX Therapeutics shares in Q3 2017, an estimated $946K.
TFS Capital first reported a position in CytomX Therapeutics in Q1 2017 and held it in 2 quarters.
TFS Capital's CytomX Therapeutics position peaked at $946K in Q2 2017.
97 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.